These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 25877635)

  • 61. Search for specific biomarkers of IFNβ bioactivity in patients with multiple sclerosis.
    Malhotra S; Bustamante MF; Pérez-Miralles F; Rio J; Ruiz de Villa MC; Vegas E; Nonell L; Deisenhammer F; Fissolo N; Nurtdinov RN; Montalban X; Comabella M
    PLoS One; 2011; 6(8):e23634. PubMed ID: 21886806
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways?
    Fine D; Dattani A; Moreira I; Giovannoni G; Marta M
    Mult Scler Relat Disord; 2015 Jan; 4(1):88-91. PubMed ID: 25787060
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antibodies against interferon-beta in neuromyelitis optica patients.
    Asgari N; Kyvik KO; Steenstrup T; Stenager E; Lillevang ST
    J Neurol Sci; 2014 Apr; 339(1-2):52-6. PubMed ID: 24477087
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response.
    Hesse D; Krakauer M; Lund H; Søndergaard HB; Langkilde A; Ryder LP; Sorensen PS; Sellebjerg F
    Neurology; 2010 May; 74(18):1455-62. PubMed ID: 20439848
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.
    Jungedal R; Lundkvist M; Engdahl E; Ramanujam R; Westerlind H; Sominanda A; Hillert J; Fogdell-Hahn A
    Mult Scler; 2012 Dec; 18(12):1775-81. PubMed ID: 22551640
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.
    van der Voort LF; Gilli F; Bertolotto A; Knol DL; Uitdehaag BM; Polman CH; Killestein J
    Arch Neurol; 2010 Apr; 67(4):402-7. PubMed ID: 20142519
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Implications of neutralising antibodies on therapeutic efficacy.
    Bertolotto A
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S29-32. PubMed ID: 19200862
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Interferon Signature's Members, a Novel Altered Correlation upon Interferon-β Treatment in Multiple Sclerosis Patients.
    Jabbari S; Hosseinpourfeizi M; Safaralizadeh R; Baradaran B
    Curr Mol Med; 2024; 24(10):1301-1306. PubMed ID: 37842895
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ingested Type I Interferon-State of the Art as Treatment for Autoimmunity Part 2.
    Brod SA
    Pharmaceuticals (Basel); 2010 Apr; 3(4):1108-1121. PubMed ID: 27713291
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN-β.
    Bustamante MF; Morcillo-Suárez C; Malhotra S; Rio J; Leyva L; Fernández O; Zettl UK; Killestein J; Brassat D; García-Merino JA; Sánchez AJ; Urcelay E; Alvarez-Lafuente R; Villar LM; Alvarez-Cermeño JC; Farré X; Lechner-Scott J; Vandenbroeck K; Rodríguez-Antigüedad A; Drulovic JS; Martinelli Boneschi F; Chan A; Oksenberg J; Navarro A; Montalban X; Comabella M
    Neurol Neuroimmunol Neuroinflamm; 2015 Oct; 2(5):e154. PubMed ID: 26445728
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Deep morphea induced by interferon-β1b injection.
    Lee EY; Glassman SJ
    JAAD Case Rep; 2016 May; 2(3):236-8. PubMed ID: 27408930
    [No Abstract]   [Full Text] [Related]  

  • 72. Self-fused concatenation of interferon with enhanced bioactivity, pharmacokinetics and antitumor efficacy.
    Hu J; Shi J; Yuan Y; Li S; Zhang B; Dong H; Zhong Q; Xie Q; Bai X; Li Y
    RSC Adv; 2022 Sep; 12(43):28279-28282. PubMed ID: 36320276
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus.
    Fassbinder T; Saunders U; Mickholz E; Jung E; Becker H; Schlüter B; Jacobi AM
    Arthritis Res Ther; 2015 Apr; 17(1):92. PubMed ID: 25890338
    [TBL] [Abstract][Full Text] [Related]  

  • 74. IFN-β Selectively Inhibits IL-2 Production through CREM-Mediated Chromatin Remodeling.
    Otero DC; Fares-Frederickson NJ; Xiao M; Baker DP; David M
    J Immunol; 2015 Jun; 194(11):5120-8. PubMed ID: 25888642
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Interferon-β suppresses murine Th1 cell function in the absence of antigen-presenting cells.
    Boivin N; Baillargeon J; Doss PM; Roy AP; Rangachari M
    PLoS One; 2015; 10(4):e0124802. PubMed ID: 25885435
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study.
    Comi G; De Stefano N; Freedman MS; Barkhof F; Uitdehaag BM; de Vos M; Marhardt K; Chen L; Issard D; Kappos L
    J Neurol Neurosurg Psychiatry; 2017 Apr; 88(4):285-294. PubMed ID: 28039317
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria.
    Solaro C; Cella M; Signori A; Martinelli V; Radaelli M; Centonze D; Sica F; Grasso MG; Clemenzi A; Bonavita S; Esposito S; Patti F; D'Amico E; Cruccu G; Truini A;
    J Neurol; 2018 Apr; 265(4):828-835. PubMed ID: 29404736
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study.
    Laroni A; Signori A; Maniscalco GT; Lanzillo R; Russo CV; Binello E; Lo Fermo S; Repice A; Annovazzi P; Bonavita S; Clerico M; Baroncini D; Prosperini L; La Gioia S; Rossi S; Cocco E; Frau J; Torri Clerici V; Signoriello E; Sartori A; Zarbo IR; Rasia S; Cordioli C; Cerqua R; Di Sapio A; Lavorgna L; Pontecorvo S; Barrilà C; Saccà F; Frigeni B; Esposito S; Ippolito D; Gallo F; Sormani MP;
    Neurology; 2017 Nov; 89(22):2222-2229. PubMed ID: 29093064
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study.
    Ernst FR; Barr P; Elmor R; Wong SL
    Curr Med Res Opin; 2017 Dec; 33(12):2099-2106. PubMed ID: 28906152
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial.
    Ozakbas S; Cinar BP; Kosehasanoğullari G; Kahraman T; Oz D; Kursun BB
    Clin Neurol Neurosurg; 2017 Sep; 160():69-72. PubMed ID: 28689102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.